Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.
Lisa Zimmer(The University of Sydney), Dirk Schadendorf(National Center for Tumor Diseases), Patrick Terheyden(University Hospital Schleswig-Holstein), Jochen Utikal(German Cancer Research Center), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Eckhart Kämpgen(Universitätsklinikum Erlangen), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Axel Hauschild(University Hospital Schleswig-Holstein), Thomas Eigentler(University Children's Hospital Tübingen), Carola Berking(Universitätsklinikum Erlangen), Michael Fluck(Fachklinik Hornheide), Rainer Rompel, Zeinab Jradi(University of Tübingen), Carmen Loquai(Johannes Gutenberg University Mainz), Felix Kiecker(Humboldt-Universität zu Berlin), Rudolf Stadler(University Hospitals of the Ruhr-University of Bochum), Julia-Marianne Vaubel(University of Duisburg-Essen), Claus Garbe(University of Tübingen)
Cited by 8
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k